Rallybio Corporation
RLYB
$4.82
$0.051.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 212.00K | 212.00K | 212.00K | 38.00K | 299.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 212.00K | 212.00K | 212.00K | 38.00K | 299.00K |
| Cost of Revenue | 500.00K | 618.00K | 5.73M | 7.39M | 863.00K |
| Gross Profit | -288.00K | -406.00K | -5.51M | -7.35M | -564.00K |
| SG&A Expenses | 2.99M | 4.20M | 4.16M | 4.26M | 4.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.14M | 10.27M | 9.88M | 11.65M | 12.37M |
| Operating Income | -6.93M | -10.06M | -9.67M | -11.61M | -12.07M |
| Income Before Tax | 16.02M | -9.70M | -9.44M | -11.04M | -11.47M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.02M | -9.70M | -9.44M | -11.04M | -11.47M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.02M | -9.70M | -9.44M | -11.04M | -11.47M |
| EBIT | -6.93M | -10.06M | -9.67M | -11.61M | -12.07M |
| EBITDA | -6.89M | -10.03M | -9.64M | -11.58M | -12.03M |
| EPS Basic | 2.84 | -1.73 | -1.69 | -1.98 | -2.06 |
| Normalized Basic EPS | -0.72 | -1.08 | -1.05 | -1.24 | -1.31 |
| EPS Diluted | 2.84 | -1.73 | -1.69 | -1.98 | -2.06 |
| Normalized Diluted EPS | -0.72 | -1.08 | -1.05 | -1.24 | -1.31 |
| Average Basic Shares Outstanding | 5.63M | 5.61M | 5.60M | 5.58M | 5.57M |
| Average Diluted Shares Outstanding | 5.63M | 5.61M | 5.60M | 5.58M | 5.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |